Last updated: February 27, 2026
What is the drug identified by NDC 49483-0081?
NDC 49483-0081 corresponds to Dynavax's HEPLISAV-B—a hepatitis B vaccine. Approved by the FDA in November 2017, HEPLISAV-B is a two-dose vaccine designed to enhance immune response in adult populations at risk for hepatitis B infection. It has gained regulatory approval for adults aged 18 and older.
Market Size and Demand
Global Hepatitis B Vaccine Market Overview
The hepatitis B vaccine market has seen consistent growth driven by increased immunization programs, rising hepatitis B prevalence, and expanding adult vaccination initiatives.
- Market valuation (2022): Estimated at USD 2.4 billion.
- Projected CAGR (2023–2028): 6.5% (ResearchAndMarkets, 2022).
- Key growth drivers: Aging populations, higher awareness, and expanded public health policies.
HEPLISAV-B Positioning
HEPLISAV-B holds approximately 15% of U.S. hepatitis B vaccine sales, competing mainly with GlaxoSmithKline's Engerix-B and Merck's Recombivax HB.
Market penetration factors:
- Bi-dose schedule (versus three doses for others) increases compliance.
- Approved for adults aged 18+, widening target demographics.
- Slightly higher efficacy in some populations.
Regional Market Dynamics
| Region |
Market Size (2022) |
CAGR (2023–2028) |
Key Factors |
| United States |
USD 1.2 billion |
7% |
Increased adult vaccination, public health efforts |
| Europe |
USD 600 million |
6.3% |
Immunization programs, aging demographics |
| Asia-Pacific |
USD 400 million |
8.4% |
Rising hepatitis B endemicity, market expansion |
Competitive Landscape
Main Competitors
- Engerix-B (GSK): First approved in 1989. Widely used; three-dose schedule.
- Recombivax HB (Merck): Approved since 1982; similar schedules.
- Heplisav-B (Dynavax): Two-dose schedule; efficacy and compliance advantages.
Market Share Distribution
| Brand |
Estimated Market Share (2022) |
Differentiators |
| Engerix-B |
45% |
Established, broad distribution |
| Recombivax HB |
30% |
Cost advantage |
| Heplisav-B |
15% |
Improved compliance, adult focus |
| Others |
10% |
Niche or emerging vaccines |
Price Projections
Current Pricing (U.S. Market, 2023)
- HEPLISAV-B: Average wholesale price approximately USD 70–90 per dose.
- Total vaccination cost: USD 140–180 for two doses.
Price Trends (2023–2028)
- Projection: Prices are expected to decline slightly as biosimilar and generic alternatives enter markets and procurement volumes increase.
- Estimated price decrease: 2–4% annually.
- Impact of policy: Reimbursement rates and government procurement strategies influence net prices; federally funded vaccination programs tend to lower costs.
Cost Comparison with Competitors
| Vaccine |
Number of Doses |
Price per Dose (USD) |
Total Cost (USD) |
Dosing Schedule |
| HEPLISAV-B |
2 |
70–90 |
140–180 |
Two doses in one month |
| Engerix-B |
3 |
40–60 |
120–180 |
Three doses over six months |
| Recombivax HB |
3 |
35–55 |
105–165 |
Three doses over six months |
Future Price Drivers
- Market entry of biosimilars: May lower prices.
- Manufacturing efficiencies: Could reduce production costs.
- Regulatory policies: Government negotiations and vaccine mandates can influence net prices.
Regulatory and Policy Impacts
- U.S. CDC: Recommends hepatitis B vaccination for adults at risk. HEPLISAV-B’s dosing schedule has increased adoption.
- Global initiatives: WHO and Gavi support immunization campaigns; vaccine price reductions critical for expanding access in low-resource settings.
- Biosimilar development: Expected to influence pricing in the next 3–5 years.
Key Takeaways
- HEPLISAV-B is positioned to capture further market share among adult hepatitis B vaccinations due to its dosing regimen and increased efficacy.
- The U.S. market for hepatitis B vaccines is projected to grow at a 6.5% CAGR through 2028.
- Price declines of 2–4% annually are projected owing to increased competition, biosimilars, and policy-driven procurement strategies.
- Regional differences significantly influence market size and growth, with the U.S. and Europe leading.
- Competitive pressures and policy shifts will impact future vaccine pricing and utilization.
FAQs
1. What is the expected market growth rate for HEPLISAV-B?
The overall hepatitis B vaccine market is expected to grow at approximately 6.5% annually through 2028.
2. How does HEPLISAV-B compare to competitors in terms of pricing?
It averages USD 70–90 per dose, with total costs around USD 140–180 for two doses, which is comparable or slightly higher than older three-dose vaccines but benefits from increased compliance.
3. What factors could influence future pricing of HEPLISAV-B?
Introduction of biosimilars, manufacturing cost reductions, and government negotiations may lead to price decreases.
4. Which regions present the most significant growth opportunities?
The U.S. and Asia-Pacific regions offer the highest growth prospects due to vaccination coverage expansion and hepatitis B prevalence.
5. What regulatory factors could impact HEPLISAV-B's market share?
FDA approvals, CDC guidelines, and GAVI procurement policies directly influence adoption and pricing.
References
[1] ResearchAndMarkets. (2022). Hepatitis B Vaccine Market Forecast.
[2] CDC. (2023). Adult Hepatitis B Vaccination Recommendations.
[3] U.S. Food and Drug Administration. (2017). FDA Approval Letter for HEPLISAV-B.
[4] Gavi, The Vaccine Alliance. (2022). Market Dynamics and Purchasing Strategies.
[5] Statista. (2023). Global Vaccine Market Data.
